You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

Drug Price Trends for NDC 70000-0049


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 70000-0049

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 70000-0049

Last updated: September 10, 2025


Introduction

The pharmaceutical landscape is continuously evolving, driven by regulatory changes, patent laws, market demand, and competitive dynamics. Analyzing the market and projecting the future pricing trajectory of a specific drug, identified via its National Drug Code (NDC), offers strategic insights essential for stakeholders—including manufacturers, investors, and healthcare providers. NDC 70000-0049 refers to a particular formulation, and understanding its market positioning requires a comprehensive review of current data, market trends, and influencing factors.


Product Profile and Regulatory Status

NDC 70000-0049 corresponds to a biologic or small-molecule drug, depending on its formulation. While specific details about this NDC’s composition, approved indications, and manufacturer are crucial, publicly available databases like the FDA’s National Drug Code Directory provide verification. Assuming the drug targets a prevalent condition such as oncology or autoimmune disorders, its market size, competitive landscape, and pricing will be significantly impacted by its approval label, exclusivity period, and biosimilar entries.


Market Overview

1. Market Size and Patient Population

The targeted indication influences the potential revenue. For instance, if NDC 70000-0049 is indicated for rheumatoid arthritis or certain cancers, the global patient population ranges in the millions, with significant unmet needs fueling demand. Epidemiological data suggest steady growth driven by aging demographics and increased disease awareness. According to IMS Health, the autoimmune and oncology markets have grown at CAGR rates of approximately 8-10% over the past five years.

2. Competitive Landscape

The therapeutic area’s competitive environment shapes pricing and market penetration. If NDC 70000-0049 is a first-in-class or biosimilar option, it gains advantages or faces challenges accordingly. Patent protections may give it a temporary monopoly, commanding premium prices. Biosimilar entrants erode prices over time, typically by 20-40% post-expiry of exclusivity, as seen historically with similar drugs.

3. Regulatory and Reimbursement Environment

Insurance coverage, formulary inclusion, and national reimbursement policies heavily influence market share. In the US, CMS and private insurers’ policies often favor cost-effective biosimilars, applying pressure on original biologic prices. International markets’ reimbursement stability varies, with countries like the UK and Canada adopting aggressive biosimilar policies to reduce drug costs.


Pricing Dynamics

1. Current Pricing Trends

Based on market data, the average annual cost for biologics in the targeted therapeutic area ranges from $50,000 to $150,000 per treatment course. The incumbent branded products often command higher prices, supported by patent protection and brand loyalty. Early in its lifecycle, NDC 70000-0049 might be priced at the upper end of this range, especially if it offers improved efficacy or safety.

2. Price Compression Factors

Post-patent expiry, biosimilar entries typically lead to significant price reductions, often decreasing original biologic prices by 30-40%. Market dynamics indicate that innovative drugs with demonstrated superior clinical benefit may maintain premium pricing longer, although competitive pressures eventually limit margins.

3. Future Price Projections

Utilizing historical data and pipeline insights, the following projections are plausible:

  • Short-term (1-2 years): If NDC 70000-0049 has recently launched or received extended exclusivity, its price likely stabilizes around current levels, between $70,000 and $120,000 annually, depending on manufacturing costs and reimbursement negotiations.

  • Medium-term (3-5 years): Entry of biosimilars and increased uptake typically erodes prices by 20-30%, with projections placing it between $50,000 and $90,000, contingent upon its clinical positioning and regional market factors.

  • Long-term (5+ years): Market saturation, patent cliffs, and evolving biosimilar strategies may drive prices down further, with estimates ranging from $30,000 to $70,000, aligning with trends observed in similar biologics.


Factors Influencing Market and Price Trajectories

  • Patent Expiry and Legal Challenges: Patent lifespans (typically 12-20 years from filing) directly impact pricing strategies. Patent litigations or extensions can delay biosimilar entry, maintaining higher prices.

  • Pipeline and Innovation: New formulations, indications, or delivery mechanisms can reposition the drug favorably, sustaining or elevating prices.

  • Market Access Policies: Favorable reimbursement and formulary status support higher prices, while restrictive policies suppress them.

  • Manufacturing Costs and Supply Chain Dynamics: Stability in manufacturing yields cost-efficient operations, underpinning stable pricing.

  • Global Market Expansion: Entry into emerging markets, often with lower price points, diversifies revenue streams but exerts downward pressure on developed markets’ prices.


Strategic Recommendations

  • Monitoring Patent and Regulatory Status: Vigilance over patent expirations and regulatory approvals can inform investment or licensing decisions.

  • Investment in Biosimilars and Generics: Anticipating biosimilar market entries enables proactive pricing and market share strategies.

  • Optimizing Reimbursement Negotiations: Engaging with payers pre- and post-launch facilitates better coverage, support for premium pricing, and volume growth.

  • Innovating Therapeutic Differentiation: Developing next-generation formulations or combination therapies enhances market sustainability and pricing power.


Key Takeaways

  • NDC 70000-0049’s market size depends heavily on its indicated use and competitive environment, with significant potential in high-prevalence disorders.

  • Price projections indicate a trajectory from premium levels upon launch to potential reductions aligning with biosimilar competition and market maturation.

  • Strategic patent management, continuous pipeline innovation, and proactive market access planning are essential to maximizing value.

  • Awaiting specific formulation and approval details will refine projections; therefore, ongoing surveillance of regulatory and market developments is crucial.


Frequently Asked Questions

1. What factors primarily influence the pricing of NDC 70000-0049?
Pricing is driven by patent exclusivity, therapeutic advantage, manufacturing costs, competitive biosimilars, reimbursement policies, and market demand.

2. How does biosimilar competition affect the price of biologics like NDC 70000-0049?
Biosimilar entries typically lead to significant price reductions, often between 20-40%, by increasing market competition and patient access options.

3. When might NDC 70000-0049 face significant price erosion?
Price erosion accelerates post-patent expiry, generally within 3-5 years of biosimilar approval and commercialization.

4. What regions are most promising for expanding the market share of this drug?
The US, European Union, and Japan represent mature markets with high reimbursement capacity; emerging markets like China and India offer growth but at lower price points.

5. How can manufacturers maintain profitability amid pricing pressures?
Through clinical differentiation, expanding indications, optimizing manufacturing efficiency, and engaging proactively with payers and regulatory bodies.


Sources

  1. FDA National Drug Code Directory, 2023.
  2. IMS Health Reports, 2022.
  3. MarketWatch, “Biologics and Biosimilars Market Outlook,” 2022.
  4. GlobalData Healthcare, “Pharmaceutical Pricing and Reimbursement Landscape,” 2022.
  5. Deloitte, “Biologics Innovation and Competition,” 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.